ArticleTheScientificWorldJournal2014
Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis.
Article in TheScientificWorldJournal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 3 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Diabetes Mellitus and COVID-19 in Adults: A Systematic Review of Pathophysiological Connections, Clinical Outcomes, and Therapeutic Considerations.International journal of molecular sciences · 2026Pooled it
- Comorbidities, Associated Diseases, and Risk Assessment in COVID-19-A Systematic Review.International journal of clinical practice · 2022Pooled it
- Pooled it
- Fasting blood glucose level is a predictor of mortality in patients with COVID-19 independent of diabetes history.Diabetes research and clinical practice · 2020Trial
- Molecular dissection of the role of ACE2 in glucose homeostasis.Physiological reviews · 2025Review
- Effects of oral antidiabetic agents on the renin-angiotensin-aldosterone system.European journal of clinical pharmacology · 2025Review
- Systematic review and meta-analysis of knowledge, attitudes, and practices regarding COVID-19 among chronic disease patients: A global perspective.Health science reports · 2024Article
- Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection.Signal transduction and targeted therapy · 2023Review
- Acute-on-chronic liver failure in patients with severe acute respiratory syndrome coronavirus 2 infection.World journal of hepatology · 2023Review
- Nutraceutical Role of Polyphenols and Triterpenes Present in the Extracts of Fruits and Leaves ofMolecules (Basel, Switzerland) · 2022Review
- Mechanisms contributing to adverse outcomes of COVID-19 in obesity.Molecular and cellular biochemistry · 2022Review
- Review
- Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study.Diabetes · 2021Article
- ACE2 function in the pancreatic islet: Implications for relationship between SARS-CoV-2 and diabetes.Acta physiologica (Oxford, England) · 2021Review
- Repurposing new drug candidates and identifying crucial molecules underlying PCOS Pathogenesis Based On Bioinformatics Analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2021Article
- Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management.Lipids in health and disease · 2021Review
- Intestinal expression of ACE2 in mice with high-fat diet-induced obesity and neonates exposed to maternal high-fat diet.Nutrition (Burbank, Los Angeles County, Calif.) · 2021Article
- An Overview of Adipose Tissue ACE2 Modulation by Diet and Obesity. Potential Implications in COVID-19 Infection and Severity.International journal of molecular sciences · 2021Review
- The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19.Acta diabetologica · 2021Review
- SARS-CoV-2: An Overview of Virus Genetics, Transmission, and Immunopathogenesis.International journal of environmental research and public health · 2021Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThiazolidinediones (TZDs) can improve hepatic steatosis in nonalcoholic steatohepatitis (NASH). Angiotensin (Ang) II, the primary effector of renin-angiotensin system (RAS), plays vital roles in the development and progression of NASH. And some AngII-mediated effects can be regulated by TZDs. Angiotensin-converting enzyme (ACE) 2, a new component of RAS, can degrade Ang II to attenuate its subsequent physiological actions. We aimed to evaluate the effects of TZDs on ACE2 expression in insulin-sensitive tissues in NASH rats.
methodsForty rats were divided into the normal control, high-fat diet (HFD), pioglitazone control, and HFD plus pioglitazone groups. After 24 weeks of treatment, we evaluated changes in liver histology and tissue-specific ACE2 expression.
resultsACE2 gene and protein expression was significantly greater in liver and adipose tissue in the HFD group compared with normal control group, while was significantly reduced in skeletal muscle. Pioglitazone significantly reduced the degree of hepatic steatosis compared with the HFD group. Pioglitazone significantly increased ACE2 protein expression in liver, adipose tissue, and skeletal muscle compared with the HFD group.
conclusionsPioglitazone improves hepatic steatosis in the rats with HFD-induced NASH and upregulates ACE2 expression in insulin-sensitive tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.